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Abstract
Background: Canadians pay amongst the highest generic drug prices in the world. In July 2010, the province of Ontario
enacted a policy that halved reimbursement for generic drugs from the public drug plan, and substantially lowered prices
for private purchases. We quantified the impact of this policy on overall generic drug expenditures in the province, and
projected the impact in other provinces had they mimicked this pricing change.
Methods: We used quarterly prescription generic drug dispensing data from the IMS-Brogan CompuScript Audit. We used
the price per unit in both the pre- and post-policy period and two economics price indexes to estimate the expenditure
reduction in Ontario. Further, we used the post-policy Ontario prices to estimate the potential reduction in other provinces.
Results: We estimate that total expenditure on generic drugs in Ontario during the second half of 2010 was between $181
and $194 million below what would be expected if prices had remained at pre-policy level. Over half of the reduction in
spending was due to savings on just 10 generic ingredients. If other provinces had matched Ontario’s prices, their
expenditures over during the latter half of 2010 would have been $445 million lower.
Discussion: We found that if Ontario’s pricing scheme were adopted nationally, overall spending on generic drugs in
Canada would drop at least $1.28 billion annually—a 5% decrease in total prescription drug expenditure. Other provinces
should seriously consider both changes to their generic drug prices and the use of more competitive bulk purchasing
policies.
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Introduction
Canadians pay amongst the highest generic drug prices in the
world [1,2]. For example, a recent comparison found that in 2007
Canada had the highest overall prices for nearly 300 commonly
used generic drugs in comparison to 11 other countries [3].
Importantly, the scale of the price differences was large—
Canadian prices were more than double those in the United
States and over five-fold higher than New Zealand. High
Canadian prices are direct consequence of provincial govern-
ments’ predominant pricing strategy for generic drugs, which sets
reimbursement for community generic drug prescriptions using a
fixed percentage that has typically been 60% to 70% of the
equivalent brand name price [1].
In an attempt to reduce provincial drug plan expenditures, in
2006 Ontario changed the price paid by the public Ontario Drug
Benefit plan (ODB) to 50% of the brand reference price. In 2010,
the Ontario government legislated further generic price reductions
[4]. Effective July 2010, the ODB price for generics would be set
at 25% of the brand and the private price for generics would
be limited to 50% of the brand equivalent immediately. The
legislation further required that the private price of generics would
drop to 25% by April 2012. These changes provoked a vocal
outcry from pharmacies that claimed the lost revenue would have
to reduce stores and services. While other provinces continue to
assess their options and wait to see the outcome in Ontario, many
continue to price generic drugs at the old 60% to 70% level [5].
To inform these decisions and future policies, we investigated
the impact of the Ontario policy from two perspectives. First, we
assessed the change in expenditures that Ontario experienced over
the first six months of their policy. Second, we estimated the
potential expenditure reductions other provinces would have
experienced if they had mimicked Ontario’s pricing strategy.
Methods
Data Sources
We obtained quarterly data from 2010 on the number of units
(e.g. tablets), prescriptions and total cost for all prescription drugs
dispensed from the IMS-Brogan CompuScript audit. These
data are drawn from a national panel of over 5,000 pharmacies
(approximately 60% of all the community pharmacies in Canada),
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These data include all prescription drugs paid for by public and
private drug plans and through out-of-pocket purchases.
We used an identifier provided by IMS-Brogan to select all
generic drugs. As generic prices are set per unit by the ODB, we
calculated the pre-policy price-per-unit (PPU) for every generic
product in Ontario using data from Quarters 1 and 2 (January–
June), and for the post-policy period using data from Quarters 3
and 4 (August–December). We also calculated a second PPU for
both periods that excluded an estimate of dispensing fees. For this
calculation, we used the allowable dispensing fee under the
Ontario Drug Benefit multiplied by the total number of volume in
the IMS-Brogan data for each generic product. As we could not
calculate a pre-policy PPU for generic drugs that were not sold in
Quarter 1 or 2, we excluded any generic product not dispensed in
either of these quarters.
Analysis of Policy Impact in Ontario
We estimated the impact of the policy on generic drug spending
in Ontario using pre-post measures based on Laspeyres and
Paasche economic indexes [7]. The first method compares actual
post-period expenditure with what expenditures would have been
in the second half of the year if the average price in Quarters 1 and
2 had continued to be used. The second estimate – required
because it can be argued that changes in prices might induce
changes in consumption – compares actual pre-policy expenditure
with what expenditures would have been if the average price in
Quarters 3 and 4 had been applied in the first half of the year.
Respectively, these methods provide an upper and lower bound on
estimated changes in expenditure due to observed changes in
prices of generic drugs. We also determined what individual
generic drugs constituted the largest portion of the change in
expenditure.
Analysis of Potential Savings in other Provinces
To estimate the potential savings of reducing generic drug prices
in other provinces, we multiplied the average Ontario post-policy
PPU and the number of units dispensed in each province. We then
calculated the potential expenditure reduction by subtracting this
total from the observed levels in each province. Finally, to make
the figures comparable across jurisdictions, we calculated per
capita amounts using population estimates from Statistics Canada
[8].
Results
Policy impact in Ontario
Figure 1 shows actual expenditure on generic drugs in Ontario
over the four quarters of 2010 and illustrates the estimated post-
policy expenditure in the scenario where prices did not change.
Comparing actual and estimated post-policy expenditures indi-
cated that generic drug expenditures in Ontario dropped $194
million due to post-policy changes in generic prices. Constructing
the analogous comparison on pre-policy period results in a similar
estimate of the change in expenditure due to changes in generic
prices: $181 million. In sum, these suggest that annualized generic
drug expenditures in Ontario dropped between $362 and $388
million. As expected, when dispensing fees are not included the
estimates increased to $240 million and $225 million, respectively.
The top 10 generic ingredients in terms of total change in
spending due to changes in price are shown in Table 1. As seen in
the table, the cost savings in Ontario were heavily concentrated:
$105 million of the estimated $194 million reduction in spending is
because of changes in the prices of these 10 generic products.
Expenditure reductions for these medicines in 2010 ranged from
11% to 32%, including markups and dispensing fees.
Estimated expenditure changes in other provinces
As shown in Table 2, we found generic drug expenditures in the
other provinces would have been approximately $890 million per
year lower if they had reimbursed generic drugs at the Ontario
price. Further, we also found wide variation in the estimated
reductions that other provinces would have realized. On a per-
capita basis, our estimated expenditure reductions ranged from an
annual savings of $34.69 per capita in BC, to a high of $68.73 in
Newfoundland.
Discussion
We found that price changes following the Ontario policy
reduced expenditure on generic drugs by between $181 and $194
million over 6 months. Further, we also found that if other
provinces mimicked the newer Ontario prices, their expenditures
would have been $445 million lower over the same 6 months. In
sum, if the Ontario prices applied nationally, the total annual
expenditure reduction would be at least $1.28 billion. This
represents a 4.9% reduction in total Canadian prescription drug
expenditures [9]. Importantly, these savings will only grow as
Ontario phases in lower prices for private purchases, and also as
more drugs become available as generics.
Our analysis should be considered in light of some limitations.
First, the Ontario policy permitted existing stock to be reimbursed
at the pre-policy price. However, this would only have acted to
make our estimates conservative, as higher prices could continue
into the post-policy period. Second, our analysis of other provinces
assumes that they would they adopt the Ontario ingredient costs,
maximum markup and dispensing fee policies. Unfortunately,
comparable data on ingredient costs for all purchasers is not
available. However, an analysis by the PMPRB suggests the
percentage that provinces spend on professional fees is differs only
a small amount: from 16% to 19% of total drug costs [10]. Third,
we had to use the Ontario Drug Benefit dispensing fee data to
Figure 1. Observed generic spending in Ontario in 2010, and
counterfactual estimates derived assuming that the pre-policy
per-unit prices continued to be used. Source: IMS Brogan,
Canadian CompuScript.
doi:10.1371/journal.pone.0023030.g001
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Unfortunately, we do not have data on the dispensing fees paid by
private plans during these quarters, or information on whether the
increased as a result of the policy. Finally, we did not include any
‘‘new’’ generics (those entering in the post-policy period), as we did
not have a pre-policy price for comparison. This would also make
our estimates conservative, as numerous high-volume drugs
continue to become available as generics.
Reductions to generic prices in other provinces would likely face
much of the same opposition and concerns that were present in
Ontario. In particular, pharmacies would oppose such cuts,
claiming they would have to reduce the number of stores.
However, prior research has shown that Canada currently has
40% more pharmacies per capita than the US, and prior research
has demonstrated that closures in Ontario would only modestly
impact geographic access [11]. Moreover, to ensure adequate
access to pharmacies in rural areas, policies can be introduced that
provide support for these pharmacies, as they were in Ontario.
In summary, Ontario’s generic price reductions reduced generic
drug expenditure in the province, and could significantly reduce
expenditures in every other province. Moreover, these savings will
only increase as the Ontario prices continue to drop for private
purchases. While these savings are impressive, there is good
evidence they could be even larger. It is likely Ontario’s prices for
many generics remain higher than they might be under a more
competitive tendering system [12,13]. Moving to such a system
would remove the arbitrary use of a reference brand price that
bears little relation to the actual cost of manufacturing. The money
that could be saved on generic drugs large, and on the same scale
as the total annual expenditure on Cancer drugs in Canada, or
some estimates of the cost of a national catastrophic drug plan
[14,15]. Other provinces should follow Ontario’s lead, and
governments and private payers should continue to foster
competition to lower generic drug prices.
Author Contributions
Conceived and designed the experiments: MRL SGM. Performed the
experiments: MRL AY SGM. Analyzed the data: AY MRL. Contributed
reagents/materials/analysis tools: MRL. Wrote the paper: MRL AY
SGM.
Table 1. Top 10 generic products by total change in spending due to changes in price in 2010 in Ontario.
Generic Product Total Prescriptions (000’s) % Spending Reduction
Estimated change in spending due
to changes in price (000’s)
Amlodipine 2,714 24.0% 2$14,772
Ramipril 3,264 23.7% 2$14,336
Pantoprazole 1,655 28.3% 2$14,167
Rabeprazole 2,292 28.5% 2$12,166
Venlafaxine 1,674 22.2% 2$10,748
Lansoprazole 1,147 31.3% 2$10,463
Olanzapine 799 32.1% 2$9,857
Omeprazole 989 23.5% 2$8,324
Citalopram 1,967 20.2% 2$7,179
Metformin 3,269 11.4% 2$3,678
Total 2$105,691
All costs are inclusive of markup and dispensing fees. Source: IMS Brogan, Canadian CompuScript.
doi:10.1371/journal.pone.0023030.t001
Table 2. Estimated potential savings in other provinces from matching Ontario generic drug prices.
Province
Generic Exp
Q3–Q4 (000’s)
Total at Ontario
Price Q3–Q4 (000’s)
Estimated Potential
6-month Savings (000’s)
Estimated Potential
Annual Savings (000’s)
Potential Annual
Savings Per Capita
BC $476,107 $397,664 $78,443 $156,886 $34.63
Alberta $437,770 $351,147 $86,623 $173,246 $46.56
Saskatchewan $120,898 $98,042 $22,855 $45,710 $43.72
Manitoba $150,763 $122,724 $28,039 $56,078 $45.39
Quebec $893,357 $727,999 $165,358 $330,716 $41.82
Nova Scotia $141,365 $119,883 $21,482 $42,964 $45.59
New Brunswick $121,638 $100,103 $21,534 $43,069 $57.29
PEI $20,366 $16,758 $3,609 $7,217 $50.73
Newfoundland $85,966 $68,448 $17,517 $35,035 $68.73
Total $2,448,230 $2,002,770 $445,460 $890,921
All costs are inclusive of markup and dispensing fees. Source: IMS Brogan, Canadian CompuScript.
doi:10.1371/journal.pone.0023030.t002
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